Q-omics provides the consensus-scored TPP1 profile across patient tissues and cancer cell-line models. TPP1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TPP1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, TPP1 protein abundance shows 27,529 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight HNSC, KIRC, and PDAC as cancer lineages where TPP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPP1 survival associations across molecular data types. TPP1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPP1 RNA expression–survival associations across cancer types. High TPP1 expression shows unfavorable associations in HNSC, KICH, STAD, LIHC and BLCA, but favorable associations in KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TPP1 RNA expression.
This table summarizes TPP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TPP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPP1 shows higher tumor expression in KIRC, HNSC, KIRP, THCA, STAD and LIHC. The KIRC box plot shows higher TPP1 RNA expression in tumor versus normal tissue (log2 FC = +1.231, t-test p < 0.001).
This table shows molecular features associated with TPP1 in patient tissues and cancer cell lines. In patient samples, TPP1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, TPP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
